Title:
REPLICATION ONCOLYTIC ADENOVIRUS HAVING ACTIVATED IMMUNE CO-STIMULATORY SIGNAL PATHWAY AND BLOCKING IMMUNE CHECKPOINT AND APPLICATION THEREOF
Document Type and Number:
WIPO Patent Application WO/2020/173123
Kind Code:
A1
Abstract:
The present invention invention belongs to the field of tumor immunotherapy, and specifically provides a new type of replication oncolytic adenovirus AD5 sPD1CD137L having activated immune co-stimulatory signal pathway and blocking immune checkpoint and application thereof in antitumor drugs. Disclosed are a design and construction method of AD5 sPD1CD137L, and the replication oncolytic adenovirus AD5 sPD1CD137L is successfully obtained; the virus can replicate specifically in tumor cells and is capable of high expression of the secretory fusion protein sPD1CD137L; the fusion protein molecule may be secreted out of the cell, performing the dual roles of immune co-stimulation and blocking of immune checkpoints. Experiments clearly indicate that the new type of replication oncolytic adenovirus of the present invention has a significant immune co-stimulation and immune checkpoint blocking function, a significant activated anti-tumor immune response, significant antitumor activity, and has great prospects and value in the development of antitumor drugs.
Inventors:
WEI JIWU (CN)
ZHANG YONGHUI (CN)
ZHANG HAILIN (CN)
WU JUNHUA (CN)
DONG JIE (CN)
ZHANG YONGHUI (CN)
ZHANG HAILIN (CN)
WU JUNHUA (CN)
DONG JIE (CN)
Application Number:
PCT/CN2019/115627
Publication Date:
September 03, 2020
Filing Date:
November 05, 2019
Export Citation:
Assignee:
UNIV NANJING (CN)
International Classes:
C07K19/00; A61K35/761; A61K38/17; A61P35/00; C12N7/01
Domestic Patent References:
| WO2017118866A1 | 2017-07-13 |
Foreign References:
| CN109312309A | 2019-02-05 | |||
| CN108728488A | 2018-11-02 | |||
| CN108165536A | 2018-06-15 | |||
| CN109069561A | 2018-12-21 |
Other References:
ZHANG, YONGHUI ET AL.: "Recombinant Adenovirus Expressing a Soluble Fusion Protein PD-1/ CD 137L Subverts the Suppression of CD 8+ T Cells in HCC", MOLECULAR THERAPY, vol. 27, no. 11, 5 August 2019 (2019-08-05)
Attorney, Agent or Firm:
JIANGSU YINCHUANG LAW FIRM (CN)
Download PDF: